Incyte Corporation (Nasdaq:INCY) today announced the closing of its
public offering of 12,075,000 shares of its common stock at a price to
the public of $9.00 per share, which includes 1,575,000 shares sold upon
exercise by the underwriters of their option to purchase additional
shares. The net proceeds to Incyte from the offering are approximately
$101.8 million, after deducting the underwriting discount and estimated
offering expenses.
The Company intends to use the net proceeds of this offering for general
corporate purposes, including research and development activities.
Goldman, Sachs & Co. acted as sole book-running manager of this offering
and Morgan Stanley & Co. Incorporated acted as joint lead manager. J.P.
Morgan Securities Inc. acted as co-manager.
The shares were issued pursuant to an effective shelf registration
statement. Printed copies of the prospectus supplement and related
prospectus relating to the offering may be obtained from Goldman, Sachs
& Co. (Attn: Prospectus Department, 85 Broad Street, New York, New York
10004, Fax: 212-902-9316 or Email at prospectus-ny@ny.email.gs.com).
This press release does not and shall not constitute an offer to sell or
the solicitation of an offer to buy the Company's common stock, nor
shall there be any sale of the common stock in any state or jurisdiction
in which such an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any state.
This information does not purport to be a complete description of the
Company’s common stock or the offering. This
offering was made only by means of a prospectus, including a prospectus
supplement, forming a part of the effective shelf registration statement.
About Incyte
Incyte Corporation is a Wilmington, Delaware-based drug discovery and
development company focused on developing proprietary small molecule
drugs to treat serious unmet medical needs. Incyte's pipeline includes
multiple compounds in Phase I and Phase II development for oncology,
inflammation and diabetes.
Forward-Looking Statements
Except for the historical information contained herein, the matters set
forth in this press release, including statements with respect to the
intended use of proceeds from the offering, are all forward-looking
statements within the meaning of the "safe harbor" provisions of the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements are subject to risks and uncertainties that may cause actual
results to differ materially, including satisfaction of the conditions
to closing of the offering, the risks associated with drug research and
development and clinical trials, unanticipated costs in research and
development efforts or other unanticipated cash requirements, and other
risks detailed from time to time in Incyte's filings with the Securities
and Exchange Commission, including its Quarterly Report on Form 10-Q for
the quarter ended June 30, 2008. Incyte disclaims any intent or
obligation to update these forward-looking statements.
Incyte Corporation
Pamela M. Murphy
Vice
President, Investor Relations &
Corporate Communications
302-498-6944
